What Should Specialty Pharmacists Know About the ReDOS Clinical Trial?
Tanios Bekaii-Saab, MD, FACP, Mayo Clinic Cancer Center, talks about key takeaways from the phase 2 ReDOS clinical trial for specialty pharmacists.
What Should Specialty Pharmacists Know About the REVERCE Clinical Trial?
Kohei Shitara, MD, Department of Gastrointestinal Oncology of National Cancer Center Hospital East, Japan, discusses the importance of the REVERCE clinical trial for specialty pharmacists.
Keytruda Improves Progression-Free Survival in Advanced Hepatocellular Carcinoma
Prior treatment with sorafenib followed by pembrolizumab (Keytruda) shows promising progression-free survival and overall survival in patients with advanced hepatocellular carcinoma.
Combo Therapy Well-Tolerate in RAS Wild-Type Metastatic Colorectal Cancer
Cetuximab (Erbitux) with pembrolizumab (Keytruda) shows promise in patients with mCRC.
Abraxane Plus Gemcitabine Shows Efficacy Treating Pancreatic Cancer
Induction therapy shows the potential to achieve disease control in patients with locally advanced pancreatic cancer.
Circulating Tumor Cell Test Effective Detecting Precancerous Lesions
A novel CTC assay showed up to 88% accuracy detecting precancerous and cancerous colorectal lesions.
Nivolumab Shows Promise Treating Gastrointestinal Tumors
Nivolumab (Opdivo) alone and in combination with ipilimumab (Yervoy) induced responses in patients with heavily pretreated gastrointestinal stromal tumors.
Cyramza Added to Chemo Regimen Not Found to Improve Gastric Cancer Survival
The addition of ramucirumab did not improve overall survival in patients with HER2-negative gastric cancer.
Combination Therapy Shows Antitumor Activity in Advanced Gastric, GEJ Adenocarcinoma
A combination VEGFR-2 inhibitor plus an antiâ€“PD-L1 agent demonstrated antitumor activity in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.
Cabozantinib Improves Survival in Advanced Hepatocellular Carcinoma
Cabometyx found to improve median overall survival by 2.2 months in patients with previously treated advanced hepatocellular carcinoma.
Extensive Intraoperative Peritoneal Lavage May Not Improve Gastric Cancer Outcomes
There may not be a significant survival benefit from a surgical procedure for gastric cancer.
Investigational Gastric Cancer Drug Elicits High Disease Control Rate
Median progression-free survival was 5.8 months among patients with HER2-positive gastric cancer who were treated with DS-8201.
2 Clarke Drive Cranbury, NJ 08512